| Overview |
| bs-1595R-Cy7 |
| MAD1 Polyclonal Antibody, Cy7 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Cow, Horse |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MAD1 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 8379 |
| Nucleus |
| mitosis arrest deficiency 1; hMAD1; HsMAD1; MAD1L1; Mitotic arrest deficient 1; Mitotic checkpoint MAD1 protein homolog; Mitotic spindle assembly checkpoint protein MAD1; PIG9; Tax binding protein 181; TP53I9 ; Tumor protein p53 inducible protein 9; TXBP181; MD1L1_HUMAN. |
| spindle microtubules. The checkpoint works by inhibiting the activity of the anaphase promoting complex, thereby preventing the degradation of several cell cycle regulators. Like other spindle checkpoint mutants, MAD1 loss-of-function mutants are sensitive to benomyl and cannot delay cell division in response to spindle depolymerization. Mad1p becomes hyperphosphorylated upon spindle depolymerization. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz